- Webinar recorded on Sat 5th March, 2016
- 0 hours 57 mins
- No Comments
Lecture 3 – Novel monitoring in hyperadrenocorticism by Laura Macfarlane. Over the past decade, trilostane has become the preferred method of medically treating both pituitary and adrenal dependent hyperadrenocorticism in dogs. Although most dogs will respond positively to therapy, some can develop signs of over-suppression. Careful monitoring which allows the clinician to determine whether adequate control has been achieved, whilst also alerting to the possibility of over-suppression, is essential. This presentation discusses the problems with the current gold standard monitoring tool, the ACTH stimulation test and the lack of emphasis placed on the owners’ satisfaction with therapy. In addition, novel methods are discussed with the ultimate aim to enable clinicians to make better, safer decisions. Laura graduated from the University of Glasgow in 2009. Following an internship at the RVC and some time in small animal practice in Northern Ireland, she returned to the University of Glasgow to commence an ECVIM internal medicine residency in 2012, which she completed in 2015. She is currently studying towards the ECVIM-CA diploma examination in March 2016. Her particular area of interest is small animal endocrinology. Her research focuses on methods of monitoring dogs receiving trilostane and she is studying towards a masters’ degree on this topic.